PAPER Sakr HF, Khalil KI, Hussein AM, Zaki MS, Eid RA, Alkhateeb M

Effect of dehydroepiandrosterone (DHEA) on memory and brain derived neurotrophic factor (BDNF) in a rat model of vascular dementia.

J Physiol Pharmacol. 2014 Feb;65(1):41-53. PubMed: 24622829

PAPER Quiedeville A, Boulouard M, Da Silva Costa-Aze V, Dauphin F, Bouet V, Freret T

5-HT6 receptor antagonists as treatment for age-related cognitive decline.

Rev Neurosci. 2014;25(3):417-27. PubMed: 24622786

PAPER Tuligenga RH, Dugravot A, Tabák AG, Elbaz A, Brunner EJ, Kivimäki M, Singh-Manoux A

Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study.

Lancet Diabetes Endocrinol. 2014 Mar;2(3):228-35. Epub 2013 Dec 19 PubMed: 24622753

PAPER Exalto LG, Biessels GJ, Karter AJ, Huang ES, Katon WJ, Minkoff JR, Whitmer RA

Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study.

Lancet Diabetes Endocrinol. 2013 Nov;1(3):183-90. Epub 2013 Aug 20 PubMed: 24622366

PAPER Tolppanen AM

Prediction of dementia in people with diabetes.

Lancet Diabetes Endocrinol. 2013 Nov;1(3):164-5. Epub 2013 Aug 20 PubMed: 24622354

PAPER Narumoto J

[Issues of health care decision-making in patients with dementia in clinical practice].

Nihon Ronen Igakkai Zasshi. 2013;50(5):635-7. PubMed: 24622134

PAPER Huang BR, Chang PC, Yeh WL, Lee CH, Tsai CF, Lin C, Lin HY, Liu YS, Wu CY, Ko PY, Huang SS, Hsu HC, Lu DY

Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection.

PLoS One. 2014;9(3):e91167. Epub 2014 Mar 12 PubMed: 24621589

PAPER Zimmermann R, Gschwandtner U, Benz N, Hatz F, Schindler C, Taub E, Fuhr P

Cognitive training in Parkinson disease: cognition-specific vs nonspecific computer training.

Neurology. 2014 Apr 8;82(14):1219-26. Epub 2014 Mar 12 PubMed: 24623840

PAPER Murata M, Okamoto T

[Depression in Parkinson's disease].

Nihon Ronen Igakkai Zasshi. 2013;50(6):752-4. PubMed: 24622217

PAPER Grieb B, Engler G, Sharott A, von Nicolai C, Streichert T, Papageorgiou I, Schulte A, Westphal M, Lamszus K, Engel AK, Moll CK, Hamel W

High-frequency stimulation of the subthalamic nucleus counteracts cortical expression of major histocompatibility complex genes in a rat model of Parkinson's disease.

PLoS One. 2014;9(3):e91663. Epub 2014 Mar 12 PubMed: 24621597

PAPER Swanson C, Emborg M

Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.

Neurol Res. 2014 Jul;36(7):634-46. Epub 2013 Dec 27 PubMed: 24620964

PAPER Jiang N, Bo H, Song C, Guo J, Zhao F, Feng H, Ding H, Ji L, Zhang Y

Increased vulnerability with aging to MPTP: the mechanisms underlying mitochondrial dynamics.

Neurol Res. 2013 Dec 19;:1743132813Y0000000296. PubMed: 24620958

PAPER Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer's Disease Neuroimaging Initiative Investigators

Sex modifies the APOE-related risk of developing Alzheimer disease.

Ann Neurol. 2014 Apr;75(4):563-73. Epub 2014 Apr 14 PubMed: 24623176

Could APP, Not Aβ, Explain Epileptic Activity in Alzheimer’s?

RESEARCH NEWS 2014-03-14 Research News People with Alzheimer’s run a high risk for seizures, as do mice that model the disease. While Aβ has seemed the most likely cause for this neuronal hyperactivity, a study in the March 12 Journal of Neuroscience suggests that the Aβ precurso

PAPER Klaassen A, Glykys J, Maguire J, Labarca C, Mody I, Boulter J

Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy.

Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19152-7. Epub 2006 Dec 4 PubMed: 17146052